Mike Hennessy Sr, Founder and Chairman, MJH Life Sciences

"Witnessing the resiliency of the oncology community in the face of challenges to both patients and their providers builds momentum in the community and is sure to lead to better outcomes going forward."

In order to properly utilize cancer therapies for personalized care, adequate molecular testing must be performed in patients who are eligible for these therapies, with this necessity becoming more and more prevalent in the treatment of gastrointestinal malignancies.

In this issue of ONCOLOGY®, we highlight some of the most important posters and presentations from the 2020 American Society of Hematology Annual Meeting & Exposition.

Amid the uncertainty, researchers, clinicians, and pharmaceutical companies rose to face one of the greatest medical challenges of our time.